Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Diego D'Agostino"'
Autor:
Stan L. Block, Ryszard Konior, Igor Smolenov, Diego D'Agostino, Leszek Szenborn, Teresa Jackowska, Daniela Toneatto, Jo Anne Welsch
Publikováno v:
Pediatric Infectious Disease Journal. 37:475-482
Current meningococcal prime-boost vaccination schedules include separate vaccines for serogroups ACWY and B. An investigational combined serogroups ABCWY vaccine (MenABCWY) was developed to protect against clinically important Neisseria meningitidis
Autor:
Daniela Toneatto, Federico Martinón-Torres, Marco Calabresi, Luis Ignacio Gonzalez-Granado, Matthew D. Snape, Susanna Esposito, Ly-Mee Yu, Anna Shcherbina, Saul N. Faust, Diego D'Agostino, Magda Campins Marti, Ewa Bernatowska, Stephen M. Hughes, Leszek Szenborn
Publikováno v:
Pediatrics. 142(3)
BACKGROUND: The capsular group B meningococcal vaccine (4CMenB) is recommended for children with complement deficiencies, asplenia, and splenic dysfunction; however, data on the immunogenicity of 4CMenB in these “at-risk” children are missing. ME
Autor:
Maurizio de Martino, Diego D'Agostino, Paolo Castiglia, Igor Smolenov, Annaelisa Tasciotti, Linda Han, Gianni Bona, Giorgio Zoppi
Publikováno v:
Vaccine. 34:3363-3370
Background MenACWY-CRM (Menveo ® ; GlaxoSmithKline) and MenACWY-TT (Nimenrix ® ; Pfizer) are two meningococcal vaccines licensed in the European Union for use in both children and adults. While both vaccines target meningococcal serogroups A, C, W
Autor:
Paul Rheault, Murdo Ferguson, Sam Henein, Anil Gupta, Terry Nolan, Kirsten P Perrett, Peter Richmond, Ferdinandus de Looze, Diego D'Agostino, Ken Heaton, María Elena Santolaya, Daniela Toneatto, Helen Marshall, Hartley Garfield, Miguel O'Ryan
Publikováno v:
Vaccine. 37(9)
Background Data on duration of protection against invasive meningococcal disease post-vaccination with the recombinant, 4-component, meningococcal serogroup B vaccine (4CMenB) are limited. We evaluated bactericidal activity persistence in adolescents
Autor:
Fiona McQuaid, Matthew D. Snape, Daniela Toneatto, Peter M. Dull, Tessa M. John, Sarah Kelly, Hannah Robinson, Ly-Mee Yu, Andrew J. Pollard, Diego D'Agostino
Publikováno v:
Canadian Medical Association Journal. 187:E215-E223
BACKGROUND: The multicomponent serogroup B meningococcal (4CMenB) vaccine induces antibodies against indicator strains of serogroup B meningococcus under various schedules. We investigated the persistence of antibodies in 5-year-old children 18-20 mo
Autor:
Murdo Ferguson, Miguel O'Ryan, Terry Nolan, Daniela Toneatto, Sam Henein, Hartley Garfield, Anil Gupta, Ken Heaton, María Elena Santolaya, Helen Marshall, Kirsten P Perrett, Ferdinandus de Looze, Diego D'Agostino, Peter Richmond, Paul Rheault
Publikováno v:
Open Forum Infectious Diseases
Background 4CMenB has been shown to be immunogenic with an acceptable safety profile in infants and young adolescents. However, no data on long-term persistence after primary vaccination in adolescents are available. This is the first study to assess
Autor:
Jo Anne Welsch, Leszek Szenborn, Teresa Jackowska, Linda Han, Diego D'Agostino, Wendy Daly, Igor Smolenov, Stan L. Block
Publikováno v:
Open Forum Infectious Diseases. 3
Autor:
Terry Nolan, Anil Gupta, Murdo Ferguson, Daniela Toneatto, Diego D'Agostino, Hartley Garfield, Helen Marshall
Publikováno v:
Open Forum Infectious Diseases
Background This phase 3b, open label, controlled, multi-center, extension study (NCT02446743) assessed the persistence of bactericidal activity at 4 years post-primary vaccination with a recombinant, 4-component, meningococcal serogroup B vaccine (4C
Autor:
Teresa Jackowska, Stan L. Block, Igor Smolenov, Diego D’Agostino, Leszek Szenborn, Linda Han, Wendy Daly, Peter M. Dull
Publikováno v:
Vaccine. 33(21)
Background A meningococcal vaccine protective against all major disease-associated serogroups (A, B, C, W and Y) is an unmet public health need. In this phase 2 observer-blinded, randomized, controlled study, two investigational meningococcal ABCWY v
Autor:
Savino Bruno, Roberto Torella, Vincenzo La Mura, Marco Romano, Amalia De Renzo, Diego D'Agostino, Mario Masarone, Fabiana Perna, Marcello Persico
BACKGROUND/AIMS:Prevalence of HCV infection in non-Hodgkin's lymphoma is high. The impact of antiviral therapy on the natural history of this subgroup of lymphomas after a successful chemotherapy regimen is still an argument of debate. METHODS:We ret
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f20440ec9925abfe006296704bc4dfc
http://hdl.handle.net/11591/188255
http://hdl.handle.net/11591/188255